Journal of Controlled Release

News

Treatment with human MITO cells (bottom right) effectively suppresses myocardial fibrosis in rat models with myocardial ischemia-reperfusion injury, compared to treatment with human CDCs (bottom left). Sham (top left) represents undamaged cardiac tissue, while Buffer (top right) represents damaged tissue without cell administration. (Masahiro Shiraishi, et al. Journal of Controlled Release. February 3, 2024)
21 Feb 2024
Regenerative therapy to treat heart failure is more effective when the mitochondria of the regenerative cells are activated prior to treatment.
fig1
21 Nov 2023
Researchers develop new method suppressing the distribution of drugs to healthy tissues, but also to rapidly removes the drugs once distributed in the body, which could improve the accuracy of imaging diagnosis of difficult cancers, reduce toxicity to healthy tissues, and furthermore improve the effectiveness of treatment.
The RNP-ssODN is designed to ensure the CRISPR-Cas9 molecule is encapsulated by the LNP. Once inside the cells, the ssODN dissociates and CRISPR-Cas9 can carry out its effect. (Haruno Onuma, Yusuke Sato, Hideyoshi Harashima. Journal of Controlled Release. February 10, 2023).
02 Mar 2023
Lipid nanoparticles have been used to encapsulate CRISPR-Cas9 and deliver it to cells in mice, where it was highly effective at knocking down expression of a target protein.
Cancer immunity induction system
31 Oct 2022
A research group at Osaka Metropolitan University has developed a drug delivery system that activates a strong cellular immune response to attack cancer cells, using one-tenth of the amount of antigen needed in the group’s previous work. By incorporating positively charged cationic lipids into liposomes and adding negatively charged pH-responsive polysaccharides to the surface, the research group increased the uptake efficiency of liposomes encapsulating cancer antigens by dendritic cells by approximately five times, which increased cytokine production by about 100 times. This increased M1-type macrophages, which activate cancer immunity, and decreased M2-type macrophages, which promote cancer growth.

Events

Sorry, no events coming up for this topic.

Researchers

Sorry, no researchers coming up for this topic.

Giants in history

Sorry, no researchers coming up for this topic.